Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA

from Love Your Heart: A Cleveland Clinic Podcast · host Cleveland Clinic Heart & Vascular Institute

Mazen Hanna, MD, Co-Director of the Cleveland Clinic’s Amyloidosis Center talks about the FDA’s recent approval of the drug Tafamidis for the treatment of ATTR Amyloidosis (also known as Amyloid Transthyretin Amyloidosis), the research behind it, what this medication does, and what this means for patients.

Episode metadata supplied by the publisher feed · Published May 21, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA

0:00 4:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Love Your Heart: A Cleveland Clinic Podcast?

This episode is 4 minutes long.

When was this Love Your Heart: A Cleveland Clinic Podcast episode published?

This episode was published on May 21, 2019.

Can I download this Love Your Heart: A Cleveland Clinic Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!